17 febrero 2015
Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received low-molecular-weight heparin (LMWH), although both groups had similar rates of subsequent heart attack or stroke, according to a new study.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/IiqHk7VlHaA/150217113958.htm
